Article successfully added.

CyFlow™ CD20 FITC

CyFlow™ CD20 FITC
Alternative Name: B1 , Bp35
Antibody: Yes
Antigen: CD20
Application: Flow cytometry
Clonality: monoclonal
Clone: LT20
Emission Maximum: 518 nm
Excitation Maximum: 490 to 495 nm
Field of Interest: Immunophenotyping, Signaling
Format/Fluorochrome: FITC
Isotype: IgG2a
Laser: Blue
Regulatory Status: RUO
Source Species: Mouse
Target Species: Human
Product number: CF552125

For Research Use Only

$235.00 USD*

Price excludes any applicable taxes plus shipping costs

Quantity 100 tests Volume 2.0 mL Immunogen Normal human lymphocytes from lymph node... more
CyFlow™ CD20 FITC

Quantity100 tests
Volume2.0 mL
ImmunogenNormal human lymphocytes from lymph node
Background InformationCD20 (B1, Bp35) is a cell surface 33-37 (depending on the degree of phosphorylation) kDa non-glycosylated surface phosphoprotein expressed on mature and most malignant B cells, but not stem cells or plasma cells (low number of the CD20 has been also detected on a subpopulation of T lymphocytes and it can be expressed on follicular dendritic cells). Its expression on B cells is synchronous with the expression of surface IgM. CD20 regulates transmembrane calcium conductance (probably functioning as a component of store-operated calcium channel), cell cycle progression and B-cell proliferation. It is associated with lipid rafts, but the intensity of this association depends on extracellular triggering, employing CD20 conformational change and/or BCR (B cell antigen receptor) aggregation. After the receptor ligation, BCR and CD20 colocalize and then rapidly dissociate before BCR endocytosis, whereas CD20 remains at the cell surface. CD20 serves as a useful target for antibody-mediated therapeutic depletion of B cells, as it is expressed at high levels on most B-cell malignancies, but does not become internalized or shed from the plasma membrane following mAb treatment.
UsageThe reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 20·µl reagent·/ 100·µl of whole blood or 10^6 cells in a suspension. The content of a vial (2 ml) is sufficient for 100 tests.
Storage BufferThe reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.

Specific References

| Hultin LE, Hausner MA, Hultin PM, Giorgi JV: CD20 (pan‑B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes. Cytometry. 1993; 14(2):196‑204. < PMID: 7523045 > | Mason D, Simmons D, Buckley C, Schwartz-Albiez R, Hadam M, Saalmuller A, Clark E, Malavasi F, Morrissey JA (Eds): Leucocyte Typing VII. Oxford University Press. 2002; 1‑945. < NLM ID: 101177131 > | Polyak MJ, Deans JP: Alanine‑170 and proline‑172 are critical determinants for extracellular CD20 epitopes: heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood. 2002 May 1; 99(9):3256‑62. < PMID: 11964291 > | Petrie RJ, Deans JP: Colocalization of the B cell receptor and CD20 followed by activation‑dependent dissociation in distinct lipid rafts. J Immunol. 2002 Sep 15; 169(6):2886‑91. < PMID: 12218101 > | Chan HT, Hughes D, French RR, Tutt AL, Walshe CA, Teeling JL, Glennie MJ, Cragg MS: CD20‑induced lymphoma cell death is independent of both caspases and its redistribution into triton X‑100 insoluble membrane rafts. Cancer Res. 2003 Sep 1; 63(17):5480‑9. < PMID: 14500384 > | Li H, Ayer LM, Polyak MJ, Mutch CM, Petrie RJ, Gauthier L, Shariat N, Hendzel MJ, Shaw AR, Patel KD, Deans JP: The CD20 calcium channel is localized to microvilli and constitutively associated with membrane rafts: antibody binding increases the affinity of the association through an epitope‑dependent cross‑linking‑independent mechanism. J Biol Chem. 2004 May 7; 279(19):19893‑901. < PMID: 14976189 > | Cragg MS, Walshe CA, Ivanov AO, Glennie MJ: The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun. 2005; 8:140‑74. < PMID: 15564720 > | Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, French RR, van Meerten T, Ebeling S, Vink T, Slootstra JW, Parren PW, Glennie MJ, van de Winkel JG: The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol. 2006 Jul 1; 177(1):362‑71. < PMID: 16785532 > | Filatov AV, Krotov GI, Zgoda VG, Volkov Y: Fluorescent immunoprecipitation analysis of cell surface proteins: a methodology compatible with mass‑spectrometry. J Immunol Methods. 2007 Jan 30; 319(1‑2):21‑33. < PMID: 17098248 > | Glennie MJ, French RR, Cragg MS, Taylor RP: Mechanisms of killing by anti‑CD20 monoclonal antibodies. Mol Immunol. 2007 Sep; 44(16):3823‑37. < PMID: 17768100 > | Kanderova V, Kuzilkova D, Stuchly J, Vaskova M, Brdicka T, Fiser K, Hrusak O, Lund‐Johansen F, Kalina T: High‐resolution antibody array analysis of childhood acute leukemia cells. Mol Cell Proteomics. 2016 Apr 1; 15(4):1246‐61. < PMID: 26785729 >